^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tolsura (SUBA-itraconazole)

    i
    Other names: SUBA-Cap
    Associations

    News

    Trials
    Company:
    Inhibitor Therap, Mayne Pharma
    Drug class:
    Hedgehog cell-signalling pathway inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    KOMET-001: First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=263, Recruiting, Kura Oncology, Inc. | N=199 --> 263
    Enrollment change
    |
    NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A)
    |
    NPM1 mutation • KMT2A rearrangement
    |
    Komzifti (ziftomenib) • Tolsura (SUBA-itraconazole)
    2years
    HITMAN: Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer (clinicaltrials.gov)
    P1/2, N=12, Completed, St Vincent's Hospital, Sydney | Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Oct 2023 | Trial primary completion date: Mar 2023 --> Aug 2023
    Trial completion • Trial completion date • Trial primary completion date
    |
    hydroxychloroquine • Tolsura (SUBA-itraconazole)
    over5years
    Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS) (clinicaltrials.gov)
    P2b, N=38, Completed, HedgePath Pharmaceuticals, Inc. | Active, not recruiting --> Completed
    Clinical • Trial completion
    |
    GLI1 (GLI Family Zinc Finger 1)
    |
    GLI1 expression
    |
    Tolsura (SUBA-itraconazole)